HS-10370

DRUG3 trials

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions

Advanced Solid TumorAdvanced Solid TumorsColorectal CancerNon-Small Cell Lung Cancer

Phase 1

Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors

RecruitingNCT05367778

Jiangsu Hansoh Pharmaceutical Co., Ltd.Advanced Solid Tumor

Start: 2022-06-03End: 2026-04-30Target: 176Updated: 2024-09-19

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

Not yet recruitingNCT06594874

Jiangsu Hansoh Pharmaceutical Co., Ltd.Advanced Solid Tumors, Non-Small Cell Lung Cancer

Start: 2024-10-31End: 2027-01-01Target: 350Updated: 2024-09-19

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Not yet recruitingNCT06963502

Jiangsu Hansoh Pharmaceutical Co., Ltd.Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer

Start: 2025-05-30End: 2030-04-30Target: 762Updated: 2025-05-09

Related Papers

Abstract CT138: Safety and efficacy of HS-10370 in KRAS G12C-mutated advanced solid tumors: Updated results from phase 1 study

Cancer Research2025-04-253 citations

Abstract CT119: Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)

Cancer Research2024-04-055 citations